Colorectal cancer (CRC) screening has been shown to reduce CRC incidence and mortality and is widely recommended. However, despite the demonstrated benefits of screening and ongoing efforts to improve screening rates, a large percentage of the population remains unscreened.
Several features are desirable for a screening test or, when repeated testing over time is instituted, a screening program. Since screening involves testing asymptomatic people who are mostly healthy, a screening test must be low risk both directly (ie, the test itself must not cause harm) and indirectly (ie, downstream risks resulting from the need for subsequent testing).
Related to this latter concept is the false-positive rate, which is a function of specificity. A test with high specificity and low false positive rate reduces risks of harm from both unnecessary testing and overdiagnosis.11 It also helps reduce the cost of screening, another desirable feature, particularly from a population-based perspective. Of course, the test should be able to detect the target lesion, making sensitivity of the test or program very important. For CRC screening, a noninvasive test as considered in this review should be able to detect curable-stage CRC, and if not on the first round of testing, then with the next round of testing, before a curable CRC becomes incurable. The degree to which a test should detect pre-cancerous lesions, most of which never progress to CRC, is debatable and beyond the scope of this review. Given the relatively long dwell time for neoplastic progression,12 a test with reasonable programmatic sensitivity may be adequate. Finally, a screening test should be widely available, affordable, and user-friendly, features required to optimize test uptake and adherence.
From a practical perspective, a "good" noninvasive test affords several advantages for both patients and health systems. Patient advantages include an opportunity to better match the screening test to individual preferences and the factors they value. 13 There is evidence that offering individuals a choice of screening options improves adherence with subsequent testing.14 From a systems or societal perspective, availability of noninvasive testing may increase the reach of CRC screening programs to include at least some of the 35% of the US population who are 4 not current with CRC screening.9 To the extent that these noninvasive approaches are less costly than their structural counterparts, they can free resources for other worthwhile interventions.
Quality of Evidence
Evidence is lacking for which screening test and strategy are best and for the cumulative benefits and harms of screening. Optimal evidence would derive from a population-based randomized trial comparing all recommended screening strategies to either "no screening" or "usual care" with CRC mortality as the primary endpoint. Of course, logistical and ethical reasons preclude the feasibility of such a trial, resulting in the need to make clinical decisions using lower quality evidence.
It is clear that noninvasive screening with stool testing works and has durable benefits.
Long-term follow-up of persons randomized to guaiac-based fecal occult blood test (gFOBT) or usual care demonstrated a 32% reduction in CRC mortality after 30 years of follow-up. 15 However, gFOBT has limitations largely because of its reliance on detecting a more nonspecific marker for bleeding (ie, heme through a peroxidase reaction). Newer tests like FIT and sDNA have clear biological advantages over gFOBT16; however, the evidence for these tests is less mature.17 For FIT and a select few sDNA18, 19 and 20 panels, there are cross-sectional, population-based studies in which colonoscopy is the reference standard. These studies provide a reasonable estimate of one-time test characteristics, providing data for simulation modeling of the cumulative benefits, harms, and costs. Studies of stool-based micro-RNA (mi-RNA), protein and metabolic markers are nearly all case-control studies, which are considered to be preliminary or hypothesis-generating because of their tendency toward bias and need for subsequent testing using a more robust study design.
Fecal Immunochemical Testing
FIT uses labeled antibody to detect the globin portion of human hemoglobin.
Mechanistically, this translates to a number of significant advantages over gFOBT (Table 2) summarized best available data and determined that overall sensitivity of one time FIT for cancer was 79% with a specificity of 94%.21 Among the subgroup of studies in which colonoscopy was the reference standard, cancer sensitivity was 71%. Not surprisingly, FIT sensitivity for advanced adenoma is significantly less and varies markedly depending upon the brand of test and cut-offs used. In one study comparing 6 qualitative FIT results, the 2 best performing tests had a sensitivity of approximately 25% for advanced adenoma. Quantitative FIT affords the opportunity to set the test to a desired hemoglobin threshold that maximizes detection and minimizes false positive rates. That being said, determining the optimal hemoglobin threshold for screening is challenging. Factors such as age and gender influence fecal hemoglobin concentration,28 partly because the prevalence of neoplasia varies by these two factors. Also, studies of FIT have lacked consistency when reporting hemoglobin quantification with a given device. Efforts to standardize reporting29 are underway and should improve the quality of the literature determining optimal threshold for a positive test. In the interim two recent systematic reviews suggest that lower thresholds (<20 μg of hemoglobin/g of stool) effectively balance test characteristics and improve cost effectiveness.21 and 30 Moving forward, it may well be possible to leverage knowledge of quantitative results to prioritize those most needing colonoscopy. A recent study identified a hemoglobin threshold of >177 μg hemoglobin/g of stool as an independent risk factor for advanced neoplasia after adjusting for factors such as sex and age (OR, 3. 
Stool-Based DNA Testing
The biological rationale is strong for measuring mutated DNA in stool. Colonocytes are continuously shed into the lumen; neoplastic cells exfoliate at a higher rate and include DNA that remains intact (ie, long) and is easier to detect than is fragmented DNA,37 Point mutations in oncogenes or tumor suppressor genes are specific for cancer and precancerous lesions. . In a parallel study of 4,482 average-risk adults, cancer sensitivity and specificity using the same marker panel were 25% and 96%, respectively.18 A second DNA panel that included APC, KRAS, and methylated vimentin, was tested during the latter half of this study and showed higher sensitivity (58%) but lower specificity (84%).18 Sensitivity for adenomas 1 cm or larger was 46%. The results from these two studies were disappointing, particularly because of the high cost of the test, which precluded repeating it at short intervals.
Although this first generation sDNA test was recommended by some guideline organizations,38 and 39 its use in clinical practice was undetectable.
Subsequent studies included better markers, buffers for stool stabilization, and more analytically sensitive measurement. Ahlquist and colleagues40 used quantitative allele-specific real-time target and signal amplification to test 4 methylated genes (NDRG4, BMP3, vimentin, and TFPI2), KRAS, and hemoglobin by immunoassay on archived specimens from 252 subjects with CRC, 293 colonoscopy-negative controls, and 133 subjects with adenomas 1 cm or larger.
At respective specificities for CRC and large adenomas of 90% and 89%, sensitivities were 85% for CRC and 54% for large adenomas, with no difference in sensitivity between proximal and distal CRCs or large adenomas. These encouraging findings led to the pivotal study for this marker panel, in which nearly 10,000 asymptomatic persons 50 to 84 years of age were tested with commercially available FIT and a multitarget sDNA panel, which consists of molecular assays for aberrantly methylated BMP3 and NDRG4 promoter regions, mutant KRAS and β- Of the cancer-related fecal proteins, tumor M2 pyruvate kinase (M2-PK) has received the most attention as a potential stool biomarker for cancer screening. A recently reported metaanalysis summarized 10 observational studies (6 case-control and 4 cohort) of M2-PK and only included those studies where colonoscopy was performed in all study participants. 43 The pooled CRC sensitivity and specificity were 79% and 81%, respectively. The authors specifically looked at 4 studies that compared M2-PK to FIT and found that the diagnostic odds ratio favored FIT (67.2 for FIT vs 9.5 for M2-PK, respectively).
Although there is no single fecal protein biomarker superior to FIT, there may be a role for use of these tests either in combination with FIT or applied as a panel of tests. Leen and colleagues included a M2-PK test kit along with a FIT as part of a FIT-based program.44 During that screening round 13 advanced adenomas were detected and 2 were specifically found because M2-PK was added (FIT detected 11 of 13 lesions). However, the positivity rate of the M2-PK was extremely high (27%) relative to FIT (6%); the lower specificity of M2-PK would markedly increase colonoscopy use for a relatively small gain in detection.
Looking for a combination of fecal protein markers may eventually be possible. There have been improvements in technology to examine the metaproteomics of the gut through shotgun mass spectrometry of stool. 45 Using this approach, Verberkmoes demonstrated that about 1/3 of proteins isolated in stool come from the human host and may theoretically be a biomarker target. Karl and colleagues46 examined 6 protein markers in 551 samples collected in a cohort that was enriched with patients with known cancer. Using Bayes logistic regression modeling, they identified a pair of markers (S100A12 and hemoglobin-haptoglobin) that demonstrated high sensitivity (88%) and specificity (95%) for cancer. Importantly, these results
were not derived in a screening cohort, nor were they externally validated. Similarly, a study in 20 cancer cases and an equal number of healthy controls examined the use of fecal protein biochips with simultaneous assessment of seven different protein markers and demonstrated sensitivity for cancer of 70% and a specificity of 40%.47 Although these 2 studies provide some proof of principle regarding combination panel testing, such strategies are far from clinical implementation.
RNA Testing
Two families of RNA have been studied as markers of colorectal neoplasia. Messenger RNA (mRNAs) were investigated initially, but found to be less stable in stool than DNA. During the last several years, investigation has turned to micro-RNAs (mi-RNAs), which are 18-to 25- of cases with cancers to that of controls with no neoplasia; however, the results require independent validation. Of interest, only one differentially regulated mi-RNA (mi-106a) is 13 common to these two works, suggesting the need for independent validation, followed by largescale, population-based evaluation.
Cost Effectiveness of Noninvasive Testing
Several cost-effectiveness analyses show that CRC screening with either invasive or noninvasive tests is cost effective,52, 53, 54, 55 and 56 and annual FIT is often the first or second most cost-effective strategy in these models. In the cost-effectiveness analysis by Heitman and colleagues,52 annual FIT tests of medium and high test characteristics were the most effective and cost-effective strategies, whereas gFOBT and two (older) sDNA panels were least cost effective. More recently, Lansdorp-Vogelaar and colleagues57 used two microsimulation models to quantify the cost effectiveness of sDNA at a cost of $350 and used every 3 or 5 years among Medicare enrollees. Although sDNA at either interval provided fewer life-years and higher cost than other recommended CRC screening strategies, it would be cost effective at a cost of $40 to $60 at a 3-year interval, and at a cost of $350 if relative adherence to testing were at least 50% higher than other strategies.
Conclusions
Noninvasive testing for CRC has made great progress during the last decade and its trajectory, based on technical and analytical improvements and on active exploration of candidate markers, suggests continued rapid advancement. Both annual FIT and sDNA every 3 years are viable noninvasive strategies for average-risk CRC screening and are both endorsed by current sub-speciality guidelines.39 and 58 Although a large randomized trial comparing annual FIT to sDNA every 3 years programmatically would be welcomed, such a study may be impractical as both technologies are evolving rapidly and the results of any long-term study 14 could be outdated before completion. Optimizing use of these tests in clinical practice requires a clearer understanding of risk for advanced colorectal neoplasia among "average-risk" persons, as well as a consideration of their test characteristics for CRC and advanced, precancerous lesions, testing interval, cost, and patient preference. If progress in noninvasive marker discovery continues at its current pace, we expect further improvements in marker discrimination, higher test throughput at lower cost, and more user-friendly testing, with a resulting expected decrease in the use of colonoscopy as a primary screening test among average-risk persons. High-quality noninvasive testing is the likely conduit to achieving higher adherence to CRC screening, with anticipated continued reductions in CRC incidence and mortality. 
